Protein superfamilies

CD40 Ligand Drugs Development Market Report 2021: T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 18, 2021
Health, Pharmaceutical, Clusters of differentiation, Branches of biology, Immune system, Medical specialties, Cytokines, Protein superfamilies, Single-pass transmembrane proteins, CD40, Tumor necrosis factor superfamily, CD154, Cell biology, Trail

b'The "CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com\'s offering.\nCD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Drugs in Development, 2021 provides in depth analysis on CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted pipeline therapeutics.\nThe report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.

Key Points: 
  • b'The "CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com\'s offering.\nCD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Drugs in Development, 2021 provides in depth analysis on CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted pipeline therapeutics.\nThe report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
  • The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.\nAdditionally, the report provides an overview of key players involved in CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics development and features dormant and discontinued projects.\nThe report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.\nThe report reviews CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources.\nThe report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages.\nThe report features descriptive drug profiles for the pipeline products which includes, Product Description, Descriptive Mechanism of Action (MoA), Research and Development (R&D) brief, Licensing and Collaboration details & Other Developmental Activities.\nThe report reviews key players involved in CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics and enlists all their major and minor projects.\nThe report assesses CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics based on Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.\nThe report summarizes all the dormant and discontinued pipeline projects.\nThe report reviews latest news and deals related to CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics.\n'

2021 Drugs Development Market Report: Tumor Necrosis Factor Receptor Superfamily Member 9 - 4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 18, 2021
Health, Pharmaceutical, Medical specialties, Branches of biology, Clinical medicine, Immunology, Protein superfamilies, Single-pass transmembrane proteins, Immune system, CD137, Oncology, TNFSF9, TNF receptor superfamily, Tumor necrosis factor superfamily

b'Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Drugs in Development, 2021\nTumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Drugs in Development, 2021 provides in depth analysis on Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) targeted pipeline therapeutics.

Key Points: 
  • b'Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Drugs in Development, 2021\nTumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) - Drugs in Development, 2021 provides in depth analysis on Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) targeted pipeline therapeutics.
  • The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
  • The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.\nAdditionally, the report provides an overview of key players involved in Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics development and features dormant and discontinued projects.
  • The report analyses the pipeline products across relevant therapy areas under development targeting Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9).\nThe report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.\nThe report reviews Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources.\nThe report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages.\nThe report features descriptive drug profiles for the pipeline products which includes, Product Description, Descriptive Mechanism of Action (MoA), Research and Development (R&D) brief, Licensing and Collaboration details & Other Developmental Activities.\nThe report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics and enlists all their major and minor projects.\nThe report assesses Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics based on Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.\nThe report summarizes all the dormant and discontinued pipeline projects.\nThe report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) targeted therapeutics.\n'

Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 Antagonists

Retrieved on: 
Wednesday, February 17, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Medical specialties, Cytokines, Protein superfamilies, Single-pass transmembrane proteins, Branches of biology, Cell biology, Clusters of differentiation, Immunology, Tumor necrosis factor, TNF receptor superfamily, CD40, BeiGene, Boston Immune Technologies and Therapeutics, BeiGene

BeiGene has secured an option to an exclusive license to develop, manufacture, and commercialize BITTs proprietary TNFR2 antagonist antibodies in Asia (excluding Japan), Australia, and New Zealand.

Key Points: 
  • BeiGene has secured an option to an exclusive license to develop, manufacture, and commercialize BITTs proprietary TNFR2 antagonist antibodies in Asia (excluding Japan), Australia, and New Zealand.
  • In connection with the exclusive option and license agreement, BeiGene also invested $4 million in BITTs Series A preferred stock financing.
  • Boston Immune Technologies and Therapeutics (BITT) is a Boston, MA based company developing a novel class of antagonist antibodies targeting the TNF superfamily receptors for applications in oncology, inflammation, autoimmunity, and infectious disease.
  • BITT is also developing additional TNF superfamily antibodies including CD40 antagonists for inflammation and CD30 antagonists for oncology.

DGAP-News: Apogenix to Present at AACR Virtual Annual Meeting II

Retrieved on: 
Wednesday, June 17, 2020
Medical specialties, Proteins, Branches of biology, Protein superfamilies, Single-pass transmembrane proteins, Apoptosis, TNF receptor superfamily, Immunology, Tumor necrosis factor superfamily, CD40, TNFRSF18, Herpesvirus entry mediator

Heidelberg, Germany, June 17, 2020 - Apogenix, a biopharmaceutical company developing next generation immunotherapeutics, announced today that it will present at the AACR Virtual Annual Meeting II , which takes place online from June 22-24, 2020.

Key Points: 
  • Heidelberg, Germany, June 17, 2020 - Apogenix, a biopharmaceutical company developing next generation immunotherapeutics, announced today that it will present at the AACR Virtual Annual Meeting II , which takes place online from June 22-24, 2020.
  • Participation will be free to everyone, but registration is required to view the meeting.
  • In addition, it is evaluating the potential of its lead immunotherapy candidate asunercept in viral infections, such as COVID-19.
  • Based on its proprietary technology platform for the construction of novel TNF superfamily receptor agonists (HERA-ligands), Apogenix develops CD40, CD27, GITR, HVEM, and 4-1BB receptor agonists for cancer immunotherapy.

Tumor Necrosis Factor Receptor Superfamily Member 10B, Pipeline Review, H2 2019 - Constitutes Close to 25 Molecules - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 21, 2020
Health, Pharmaceutical, Branches of biology, Immune system, Medical specialties, Cytokines, Protein superfamilies, Single-pass transmembrane proteins, Death receptor 5, Trail, TNF receptor superfamily, CD120, Tumor necrosis factor superfamily, Tumor necrosis factor alpha

The "Tumor Necrosis Factor Receptor Superfamily Member 10B - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Tumor Necrosis Factor Receptor Superfamily Member 10B - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) pipeline Target constitutes close to 25 molecules.
  • The latest report Tumor Necrosis Factor Receptor Superfamily Member 10B - Pipeline Review, H2 2019, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
  • Tumor Necrosis Factor Receptor Superfamily Member 10B (Death Receptor 5 or TNF Related Apoptosis Inducing Ligand Receptor 2 or TRAIL Receptor 2 or DR5 or CD262 or TNFRSF10B) - Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) or Death receptor 5 (DR5) is a protein encoded by TNFRSF10B.